NCT03098589 2025-03-30Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)CelgeneCompleted1,149 enrolled
NCT02921828 2022-07-05A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mgCelgeneCompleted1,149 enrolled
NCT02921802 2022-06-14A Study of Special Use Results Surveillance of Revlimid 5mg CapsulesCelgeneCompleted4,626 enrolled
NCT02922543 2022-06-14A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of UseCelgeneCompleted361 enrolled
NCT01697839 2018-03-05Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma PatientsOncotherapeuticsCompleted110 enrolled
NCT00751205 2014-10-28Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)BayerPhase 2 Completed150 enrolled
NCT00380965 2008-02-15Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced NeuropathyNEMA Research, Inc.Phase 4 Completed23 enrolled
NCT00041795 2005-06-24Neotrofin for Treatment of Chemotherapy-Induced Peripheral NeuropathyNeoTherapeuticsPhase 2 Completed50 enrolled